INS and type 2 diabetes mellitus: Over the past decade, several small uncontrolled studies have shown improvements in glycaemic control, reductions in insulin requirements and improved quality of life for adults with T2D on CSII vs. multiple daily injections (MDI) or oral agents 69–71.